Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis

Background: Pramipexole is a dopamine full agonist approved for the treatment of Parkinson’s disease and restless legs syndrome. Its high affinity for the D3 receptor and neuroprotective, antioxidant, and anti-inflammatory activity provides a rationale for the treatment of depression. In this paper,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tundo, Antonio, Betro’, Sophia, de Filippis, Rocco, Marchetti, Fulvia, Nacca, Daniele, Necci, Roberta, Iommi, Marica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141126/
https://www.ncbi.nlm.nih.gov/pubmed/37109571
http://dx.doi.org/10.3390/life13041043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141126/
https://www.ncbi.nlm.nih.gov/pubmed/37109571
http://dx.doi.org/10.3390/life13041043

Ejemplares similares